HomeCompareNENTY vs ABBV

NENTY vs ABBV: Dividend Comparison 2026

NENTY yields 520.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NENTY wins by $83813.31M in total portfolio value
10 years
NENTY
NENTY
● Live price
520.44%
Share price
$0.01
Annual div
$0.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$83813.41M
Annual income
$60,823,388,757.34
Full NENTY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NENTY vs ABBV

📍 NENTY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNENTYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NENTY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NENTY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NENTY
Annual income on $10K today (after 15% tax)
$44,237.23/yr
After 10yr DRIP, annual income (after tax)
$51,699,880,443.74/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NENTY beats the other by $51,699,859,387.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NENTY + ABBV for your $10,000?

NENTY: 50%ABBV: 50%
100% ABBV50/50100% NENTY
Portfolio after 10yr
$41906.76M
Annual income
$30,411,706,764.55/yr
Blended yield
72.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NENTY
No analyst data
Altman Z
1.2
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NENTY buys
0
ABBV buys
0
No recent congressional trades found for NENTY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNENTYABBV
Forward yield520.44%3.06%
Annual dividend / share$0.06$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$83813.41M$102.3K
Annual income after 10y$60,823,388,757.34$24,771.77
Total dividends collected$81833.71M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NENTY vs ABBV ($10,000, DRIP)

YearNENTY PortfolioNENTY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$62,744$52,043.80$11,550$430.00+$51.2KNENTY
2$372,316$305,180.00$13,472$627.96+$358.8KNENTY
3$2,090,817$1,692,438.90$15,906$926.08+$2.07MNENTY
4$11,119,643$8,882,468.53$19,071$1,382.55+$11.10MNENTY
5$56,047,410$44,149,392.37$23,302$2,095.81+$56.02MNENTY
6$267,943,114$207,972,385.10$29,150$3,237.93+$267.91MNENTY
7$1,215,898,588$929,199,456.04$37,536$5,121.41+$1215.86MNENTY
8$5,241,770,917$3,940,759,428.19$50,079$8,338.38+$5241.72MNENTY
9$21,486,001,376$15,877,306,494.52$69,753$14,065.80+$21485.93MNENTY
10$83,813,410,229$60,823,388,757.34$102,337$24,771.77+$83813.31MNENTY

NENTY vs ABBV: Complete Analysis 2026

NENTYStock

Viaplay Group AB (publ) operates as an entertainment provider and streaming company in Sweden, Norway, Denmark, Finland, the United Kingdom, the Netherlands, and internationally. The company operates Viaplay, an online video streaming service, which offers live sports, original series, documentaries and films, and international TV releases, as well as all-time classic series, and children's animation and series; Viafree that offers a range of free-to-view content to viewers; V sport, series & film, a family of premium-TV channels that offers television entertainment; and Viaplay studios that consists of production companies, which produce original and animated content. It also operates TV3, commercial TV channel; TV6, a young male skewed channel; TV8, a channel that provides procedural drama; TV10, a channel for sporting events and documentaries; Viasat4 and TV3+ for young male audiences; TV3 PULS that offers procedural series, cooking, and lifestyle shows; TV3 Sport for sports lovers; and TV3 MAX, which shows comedy and drama series. In addition, it operates radio stations, comprising of Rix FM, Bandit Rock, Power Hit Radio, Star FM, P4 Lyden av Norge, P5 Hits, P6 Rock, P7 Klem, P8 Pop, P9 Retro, and P10 Country; NRJ, an online TV channel; Bandit, an online station; and I LIKE RADIO, an online music service, well as news, talk shows, and contests. Further, the company offers advertising services on TV channels, radio stations, and streaming services. The company was formerly known as Nordic Entertainment Group AB (publ) and changed its name to Viaplay Group AB (publ) in May 2022. Viaplay Group AB (publ) was incorporated in 2017 and is headquartered in Stockholm, Sweden.

Full NENTY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NENTY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NENTY vs SCHDNENTY vs JEPINENTY vs ONENTY vs KONENTY vs MAINNENTY vs JNJNENTY vs MRKNENTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.